TFF PHARMACEUTICALS, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 87 rows, 87 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2024-07-03: Reporting owner Weisman Harlan F; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-07-03: Reporting owner Lee Catherine Chai-zon; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-07-03: Reporting owner MILLS ROBERT S; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-07-03: Reporting owner Roberts Brandi; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-07-03 | Weisman Harlan F Director, Officer (President and CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +27,480 27,480 owned after | $1.82 exercise price | 2024-07-08 | |
| 2024-07-03 | Lee Catherine Chai-zon Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,583 1,583 owned after | $1.82 exercise price | 2024-07-08 | |
| 2024-07-03 | MILLS ROBERT S Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,165 3,165 owned after | $1.82 exercise price | 2024-07-08 | |
| 2024-07-03 | Roberts Brandi Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,165 3,165 owned after | $1.82 exercise price | 2024-07-08 | |
| 2024-07-03 | COLEMAN KIRK ALLEN Officer (Chief Financial Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,184 10,184 owned after | $1.82 exercise price | 2024-07-08 | |
| 2024-07-03 | Mikhak Zamaneh Officer (Chief Medical Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,184 10,184 owned after | $1.82 exercise price | 2024-07-08 | |
| 2024-07-03 | ROCAMBOLI STEPHEN Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,165 3,165 owned after | $1.82 exercise price | 2024-07-08 | |
| 2024-07-03 | KING THOMAS BRAXTON Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,583 1,583 owned after | $1.82 exercise price | 2024-07-08 | |
| 2023-12-13 | KING THOMAS BRAXTON Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +132,442 132,442 owned after | $0.35 exercise price | 2023-12-15 | |
| 2023-12-01 | Roberts Brandi Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +52,858 52,858 owned after | $0.36 exercise price | 2023-12-04 | |
| 2023-12-01 | MILLS ROBERT S Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +52,858 52,858 owned after | $0.36 exercise price | 2023-12-04 | |
| 2023-12-01 | ROCAMBOLI STEPHEN Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +52,858 52,858 owned after | $0.36 exercise price | 2023-12-04 | |
| 2023-12-01 | Patane Michael A Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +132,442 132,442 owned after | $0.36 exercise price | 2023-12-04 | |
| 2023-12-01 | Lee Catherine Chai-zon Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +132,442 132,442 owned after | $0.36 exercise price | 2023-12-04 | |
| 2023-03-22 | COLEMAN KIRK ALLEN Officer (Chief Financial Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $0.80 exercise price | 2023-03-24 | |
| 2023-01-20 holding as of filing | Mikhak Zamaneh Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.97 exercise price | 2023-01-20 | ||
| 2022-12-29 | ROCAMBOLI STEPHEN Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +33,475 33,475 owned after | $0.85 exercise price | 2022-12-30 | |
| 2022-12-29 | Roberts Brandi Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,968 20,968 owned after | $0.85 exercise price | 2022-12-30 | |
| 2022-12-29 | MILLS ROBERT S Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +33,475 33,475 owned after | $0.85 exercise price | 2022-12-30 | |
| 2022-12-29 | Fletcher Aaron G.L. Director | 4 | Stock Options (Right to Buy) Derivative · Indirect · To BP Directors for the benefit of Reporting Person | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +33,475 33,475 owned after | $0.85 exercise price | 2022-12-30 | |
| 2022-12-03 | Weisman Harlan F Director, Officer (President and CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,792,450 1,792,450 owned after | $1.19 exercise price | 2022-12-06 | |
| 2022-09-29 | THURMAN RANDY H Director | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −40,255 84,670 owned after | $2.50 exercise price | 2022-09-30 | |
| 2022-04-04 holding as of filing | Roberts Brandi Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.90 exercise price | 2022-04-04 | ||
| 2021-09-22 | CANO CHRISTOPHER Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +43,000 200,000 owned after | $7.93 exercise price | 2021-09-24 | |
| 2021-03-15 | ROCAMBOLI STEPHEN Director | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −14,756 107,673 owned after | $2.50 exercise price | 2021-03-17 | |
| 2021-03-15 | ROCAMBOLI STEPHEN Director | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,250 102,423 owned after | $5.00 exercise price | 2021-03-17 | |
| 2021-03-15 | Mattes Glenn R. Director, Officer (President and CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 944,227 owned after | $2.50 exercise price | 2021-03-17 | |
| 2021-03-15 | COLEMAN KIRK ALLEN Officer (CFO, Secretary and Treasurer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 277,883 owned after | $2.50 exercise price | 2021-03-17 | |
| 2021-02-16 | Mattes Glenn R. Director, Officer (President and CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −40,000 994,227 owned after | $2.50 exercise price | 2021-02-18 | |
| 2021-02-16 | COLEMAN KIRK ALLEN Officer (CFO, Secretary and Treasurer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 282,883 owned after | $2.50 exercise price | 2021-02-18 | |
| 2021-02-10 | MILLS ROBERT S Director | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −700 151,319 owned after | $2.50 exercise price | 2021-02-12 | |
| 2021-01-20 | MILLS ROBERT S Director | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,600 152,019 owned after | $2.50 exercise price | 2021-01-20 | |
| 2021-01-19 | MILLS ROBERT S Director | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −55,100 164,619 owned after | $2.50 exercise price | 2021-01-20 | |
| 2021-01-15 | Mattes Glenn R. Director, Officer (President and CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −40,000 1,034,227 owned after | $2.50 exercise price | 2021-01-20 | |
| 2021-01-15 | COLEMAN KIRK ALLEN Officer (CFO, Secretary and Treasurer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 287,883 owned after | $2.50 exercise price | 2021-01-20 | |
| 2020-12-23 | Mattes Glenn R. Director, Officer (President and CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −30,000 1,074,227 owned after | $2.50 exercise price | 2020-12-29 | |
| 2020-12-23 | COLEMAN KIRK ALLEN Officer (CFO, Secretary and Treasurer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 292,883 owned after | $2.50 exercise price | 2020-12-29 | |
| 2020-12-11 | MILLS ROBERT S Director | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −22,794 219,719 owned after | $2.50 exercise price | 2020-12-15 | |
| 2020-12-07 | WINDSOR JAMES BRIAN Director, Officer (Chief Science Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 134,429 owned after | $2.50 exercise price | 2020-12-09 | |
| 2020-11-11 | THURMAN RANDY H Director | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −34,504 124,925 owned after | $2.50 exercise price | 2020-11-13 | |
| 2020-11-11 | ROCAMBOLI STEPHEN Director | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,722 122,429 owned after | $2.50 exercise price | 2020-11-13 | |
| 2020-11-10 | ROCAMBOLI STEPHEN Director | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −21,278 138,151 owned after | $2.50 exercise price | 2020-11-13 | |
| 2020-11-10 | COLEMAN KIRK ALLEN Officer (CFO, Secretary, and Treasurer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 302,883 owned after | $2.50 exercise price | 2020-11-13 | |
| 2020-11-10 | Mattes Glenn R. Director, Officer (President and CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −108,830 1,104,227 owned after | $2.50 exercise price | 2020-11-13 | |
| 2020-09-29 holding as of filing | CANO CHRISTOPHER Officer (Chief Operating Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.50 exercise price | 2020-09-29 | ||
| 2020-09-29 holding as of filing | CANO CHRISTOPHER Officer (Chief Operating Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $5.16 exercise price | 2020-09-29 | ||
| 2020-09-29 holding as of filing | CANO CHRISTOPHER Officer (Chief Operating Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $5.81 exercise price | 2020-09-29 | ||
| 2020-09-29 holding as of filing | CANO CHRISTOPHER Officer (Chief Operating Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $13.65 exercise price | 2020-09-29 | ||
| 2020-09-29 holding as of filing | CANO CHRISTOPHER Officer (Chief Operating Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $14.06 exercise price | 2020-09-29 | ||
| 2020-08-24 | ROCAMBOLI STEPHEN Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 159,429 owned after | $13.65 exercise price | 2020-08-26 | |
| 2020-08-24 | MILLS ROBERT S Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,300 242,512 owned after | $13.65 exercise price | 2020-08-26 | |
| 2020-08-24 | THURMAN RANDY H Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 159,429 owned after | $13.65 exercise price | 2020-08-26 | |
| 2020-08-24 | Fairbairn Malcolm Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,200 105,455 owned after | $13.65 exercise price | 2020-08-26 | |
| 2020-08-24 | COLEMAN KIRK ALLEN Officer (CFO, Secretary, and Treasurer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 317,883 owned after | $13.65 exercise price | 2020-08-26 | |
| 2020-08-24 | Weisman Harlan F Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 159,429 owned after | $13.65 exercise price | 2020-08-26 | |
| 2020-08-24 | Mattes Glenn R. Director, Officer (President and CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +152,000 1,213,057 owned after | $13.65 exercise price | 2020-08-26 | |
| 2020-08-24 | WINDSOR JAMES BRIAN Director, Officer (Chief Science Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 159,429 owned after | $13.65 exercise price | 2020-08-26 | |
| 2020-08-24 | Fletcher Aaron G.L. Director | 4 | Stock Options (Right to Purchase) Derivative · Indirect · To BP Directors for the benefit of Reporting Person | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 159,429 owned after | $13.65 exercise price | 2020-08-26 | |
| 2020-02-14 | Fairbairn Malcolm Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +92,255 92,255 owned after | $5.06 exercise price | 2020-02-19 | |
| 2019-12-20 | COLEMAN KIRK ALLEN Officer (CFO, Secretary, and Treasurer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 277,883 owned after | $5.16 exercise price | 2019-12-26 | |
| 2019-11-29 | MILLS ROBERT S Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,838 212,212 owned after | $5.00 exercise price | 2020-08-26 | |
| 2019-11-29 | Mattes Glenn R. Director, Officer (President and CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +89,952 1,061,057 owned after | $5.00 exercise price | 2020-08-26 | |
| 2019-11-29 | WINDSOR JAMES BRIAN Director, Officer (Chief Science Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,623 139,429 owned after | $5.00 exercise price | 2019-12-03 | |
| 2019-11-29 | Weisman Harlan F Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,623 139,429 owned after | $5.00 exercise price | 2019-12-03 | |
| 2019-11-29 | THURMAN RANDY H Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,623 139,429 owned after | $5.00 exercise price | 2019-12-03 | |
| 2019-11-29 | ROCAMBOLI STEPHEN Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,623 139,429 owned after | $5.00 exercise price | 2019-12-03 | |
| 2019-11-29 | MILLS ROBERT S Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +2,351 186,374 owned after | $5.00 exercise price | 2019-12-03 | |
| 2019-11-29 | Mattes Glenn R. Director, Officer (President and CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,214 971,105 owned after | $5.00 exercise price | 2019-12-03 | |
| 2019-11-29 | Fletcher Aaron G.L. Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,623 139,429 owned after | $5.00 exercise price | 2019-12-03 | |
| 2019-11-29 | COLEMAN KIRK ALLEN Officer (CFO, Secretary, and Treasurer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,920 227,883 owned after | $5.00 exercise price | 2019-12-03 | |
| 2019-10-29 | Mattes Glenn R. Director, Officer (President and CEO) | 4/A | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +332,868 945,891 owned after | $5.00 exercise price | 2019-10-30 | |
| 2019-10-29 | ROCAMBOLI STEPHEN Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +43,794 135,806 owned after | $5.00 exercise price | 2019-10-29 | |
| 2019-10-29 | WINDSOR JAMES BRIAN Director, Officer (Chief Science Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +43,794 135,806 owned after | $5.00 exercise price | 2019-10-29 | |
| 2019-10-29 | Weisman Harlan F Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +43,794 135,806 owned after | $5.00 exercise price | 2019-10-29 | |
| 2019-10-29 | THURMAN RANDY H Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +43,794 135,806 owned after | $5.00 exercise price | 2019-10-29 | |
| 2019-10-29 | Mattes Glenn R. Director, Officer (President and CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +332,868 945,891 owned after | $5.00 exercise price | 2019-10-29 | |
| 2019-10-29 | COLEMAN KIRK ALLEN Officer (CFO, Secretary, and Treasurer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +71,963 221,963 owned after | $5.00 exercise price | 2019-10-29 | |
| 2019-10-24 holding as of filing | WINDSOR JAMES BRIAN Director, Officer (Chief Science Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.50 exercise price | 2019-10-24 | ||
| 2019-10-24 holding as of filing | WINDSOR JAMES BRIAN Director, Officer (Chief Science Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.50 exercise price | 2019-10-24 | ||
| 2019-10-24 holding as of filing | Weisman Harlan F Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.50 exercise price | 2019-10-24 | ||
| 2019-10-24 holding as of filing | THURMAN RANDY H Director | 3 | Stock Options (Right to Buy) Derivative · Direct | Holding | $2.50 exercise price | 2019-10-24 | ||
| 2019-10-24 holding as of filing | ROCAMBOLI STEPHEN Director | 3 | Stock Options (Right to Buy) Derivative · Direct | Holding | $2.50 exercise price | 2019-10-24 | ||
| 2019-10-24 holding as of filing | MILLS ROBERT S Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.50 exercise price | 2019-10-24 | ||
| 2019-10-24 holding as of filing | MILLS ROBERT S Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.50 exercise price | 2019-10-24 | ||
| 2019-10-24 holding as of filing | Mattes Glenn R. Director, Officer (President and CEO) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.50 exercise price | 2019-10-24 | ||
| 2019-10-24 holding as of filing | Mattes Glenn R. Director, Officer (President and CEO) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.50 exercise price | 2019-10-24 | ||
| 2019-10-24 holding as of filing | COLEMAN KIRK ALLEN Officer (CFO, Secretary, and Treasurer) | 3 | Stock Options (Right to Buy) Derivative · Direct | Holding | $2.50 exercise price | 2019-10-24 |